NCT04291664 - PK and Dose Escalation and Expansion Study of DST-2970 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2020

Primary Completion Date

January 27, 2023

Study Completion Date

January 27, 2023

Conditions

Prostate Cancer

Interventions

DRUG

Abiraterone Acetate

Abiraterone Acetate 1000mg will be administered orally once daily

DRUG

Prednisone 5Mg Tab

"Prednisone 5mg will be administered orally twice daily with Abiraterone Acetate 1000mg~Prednisone 5mg will be administered orally twice daily with DST-2970 for 28 days after dosing of Abiraterone Acetate is stopped"

DRUG

DST-2970 (Abiraterone)

DST-2970 will be administered orally twice daily for 28 days (for every cycle) after dosing of Abiraterone Acetate is stopped

Trial Locations (5)

10029

Icahn School of Medicine at Mount Sinai, New York

29572

Carolina Urologic Research Center, Myrtle Beach

33136

University of Miami, Miami

70121

Ochsner Clinic Foundation, New Orleans

78229

Mays Cancer Center, San Antonio